TY  - JOUR
AU  - Ernst, A.
AU  - Schlattmann, P.
AU  - Waldfahrer, F.
AU  - Westhofen, M.
TI  - M06 Olesoxime Treatment Inhibits The Formation Of Mhtt Fragments Through Suppression Of Calpain Activity, And Leads To Behavioural And Neurological Improvements In The Bachd Rat
JO  - Journal of neurology, neurosurgery, and psychiatry
VL  - 85
IS  - Suppl 1
SN  - 0022-3050
CY  - London
PB  - BMJ Publishing Group
M1  - DZNE-2020-04464
SP  - A96-A96
PY  - 2017
AB  - The BEMED study (BMJ 2016; 352: DOI 10.1136) was designed as multi-centric, double-blind, plaebo-controlled study in patients with Menière's disease. It should compare a low-level (2 × 24 mg/d) vs. high-level (3 × 48 mg/d) betahstine intake vs. placebo. The primary endpoint was the 'number of vertigo attacks lasting longer than 20 min as documented in a patient's diary'. The main finding of the study was that betahistine did not significantly better reduced the number of vertigo attacks than placebo. Therefore, the BEMED study should be critically discussed in the present paper.
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Betahistine: therapeutic use
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Female
KW  - Germany
KW  - Humans
KW  - Male
KW  - Meniere Disease: classification
KW  - Meniere Disease: diagnosis
KW  - Meniere Disease: drug therapy
KW  - Middle Aged
KW  - Young Adult
KW  - Betahistine (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:28850992
DO  - DOI:10.1136/jnnp-2014-309032.278
UR  - https://pub.dzne.de/record/138142
ER  -